1Cortizo AM, Sedlinsky C, McCarthy AD, et al.Osteogenic action of the anti-diabetic drug metformin on osteogenic in culture[J].Eur J Pharmacol, 2006, 536(1-2): 38-46.
2Kanazawa, Yamaguchi T, Yamamoto M, et al.Reatationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebralfractures in type 2 diabetes mullitus [J].Bone Miner Metab, 2010, 28(5): 554-560.
3Federation International Diabetes,IDF Diabetes Atlas[M].6th ed.2013:Brussels,Belgium:International Diabetes Federation.
4Maric C,Hall JE.Obesity,metabolic syndrome and diabetic nephropathy[J].Contrib Nephrol,2011,170(1):28-35.
5Selvin E,Ning Y,Steffes MW,et al.Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes[J].Diabetes,2011,60(1):298-305.
6Vreges B.The impact of prandial glucose regulation in practice[J].Diabetes Nutr Metab,2002,15(suppl 6):28-32.
7Panchapakesan U,Mather A,Pollock C.Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease[J].Clin Sci(Lond),2013,124(1):17.
8Riddle Matthew C,Pfeffer M A.The Evaluation of Lixisenatide in Acute Coronary Syndrome—The Results of ELIXA.American Diabetse Association 75th Scientific Sessions[R].2015:Boston,MA.
